Loading
Siltuximab (Sylvant) is an antibody that neutralises the inflammatory messenger interleukin-6. It is the only approved treatment for multicentric Castleman disease, a rare lymph node disorder, in people without HIV or HHV-8 infection.
Siltuximab was approved by the FDA in April 2014 and by the EU in the same year for multicentric Castleman disease in HIV-negative and HHV-8-negative patients, on a randomised placebo-controlled phase 2 trial of 79 patients in which durable tumour and symptomatic responses occurred only in the siltuximab arm. Castleman disease is a lymphoproliferative disorder rather than a cancer, but it is managed by haematologist-oncologists and the NCI lists siltuximab among cancer drugs. Infusion is every three weeks indefinitely in responders. Because IL-6 blockade suppresses C-reactive protein and fever, infections may be masked; hypertriglyceridaemia and neutropenia occur. Tocilizumab, which blocks the IL-6 receptor, is used in the same disease off label.
Binds interleukin-6 directly and prevents it engaging soluble and membrane-bound IL-6 receptors, cutting the cytokine drive behind Castleman disease. Connects to Interleukin-6 and IL-6 receptor.
1.Siltuximab binds Interleukin-6 and IL-6 receptor.
| Region | Year | Indication |
|---|---|---|
| US | 2014 | Multicentric Castleman disease in HIV-negative and HHV-8-negative patients |
| EU | 2014 | Multicentric Castleman disease in HIV-negative and HHV-8-negative adults |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Siltuximab" OR ABSTRACT:"Siltuximab" OR TITLE:"Sylvant" OR ABSTRACT:"Sylvant") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Siltuximab, not a curated reading list.
Shares Tocilizumab, Johnson & Johnson, Monoclonal antibodies.
Shares Tocilizumab, Monoclonal antibodies.
Shares Tocilizumab, Monoclonal antibodies.
Shares Tocilizumab, Monoclonal antibodies.
Shares Tocilizumab, Monoclonal antibodies.
Shares Johnson & Johnson, Monoclonal antibodies.
Shares Johnson & Johnson, Monoclonal antibodies.
Shares Johnson & Johnson, Monoclonal antibodies.